Topical Oxybutynin for Sweaty Palms: Four Lotion Trial Findings

A palm lotion trial can answer a question about that preparation. It takes a separate prescribing discussion to apply the result to a different gel, body site or sweating pattern.

The four-week trial counted measured sweat reduction

The 2023 Japanese trial¹ included 284 patients aged 12 or older with primary palmar hyperhidrosis: 144 received 20% oxybutynin hydrochloride lotion and 140 received placebo on both palms, once daily for four weeks. A device measured sweat; response meant at least a 50% reduction from baseline.¹

52.8% responded with the lotion versus 24.3% with placebo, a difference of 28.5 percentage points. That was statistically significant, but it was a reduction threshold, not complete dryness. Hisamitsu sponsored the study and supplied the products; four authors were company employees and two disclosed consulting fees.¹

The year-long extension had no placebo comparison

The extension evaluated 52 weeks of treatment, with 125 people in the safety analysis. Most had completed the earlier trial and chosen to continue; a small number were new participants. It was open-label and uncontrolled, so reported continuing benefit cannot establish a year-long advantage over placebo or persistence after stopping.²

36% had an adverse reaction judged related to treatment, including 26.4% with application-site reactions. 1.6% stopped treatment because of adverse events. Thirst and dry throat were also reported. Most events were mild. The authors disclosed Hisamitsu employment or consulting relationships.²

Palm application did not prevent systemic exposure

The manufacturer’s February 2026 Japanese dossier reports oxybutynin in blood during the extension. Its precautions include heat-related body-temperature increases, blurred vision, dizziness and sleepiness. It also warns against touching the eyes or handling contact lenses before the treated hands have been washed after waking.³

Bring glaucoma, bladder-emptying or bowel problems and other medicines into the prescribing discussion. Ask how to handle eye exposure and hot-weather work. The dossier’s trial criteria excluded sweating attributed to menopause or another underlying cause; those patterns should not inherit the trial result automatically.³

Identify the product before borrowing its results

APOHIDE’s Japanese approval dates to March 27, 2023, and its indication is primary palmar hyperhidrosis. That identifies a particular lotion and jurisdiction.³

If a US prescription is compounded, it is not FDA-approved; FDA does not verify a compounded medicine’s safety, effectiveness or quality before marketing. Compounding may meet an individual need when an approved medicine is unsuitable, but a matching ingredient name does not establish interchangeability with a study product.⁴

Ask for the complete formulation, strength, pharmacy, intended body site and storage instructions. Have the prescriber explain which study supports that preparation and what would trigger a review. Do not use trial percentages to devise a stronger mixture or move a product to another body site.

Name the task you want treatment to improve

In “The Step-Up Conversation” in Arms Up, the discussion starts with the affected zone, its four-point score, the pattern and previous treatments. Add a task such as handling paper, using a touchscreen or gripping a steering wheel, then agree on a review date.

Our oral oxybutynin evidence guide covers the tablet studies. Those results should be kept distinct from this palm-lotion trial.